← All organizations
Highest phase reached
Phase 2
First clinical trial
Feb 1, 2010Last known activity
Mar 1, 2016
Acquired by PTC Therapeutics on Oct 30, 2019
Timeline
1940s
- Nov 19, 1946
methylergometrine— NDA Secondary Org
2000s
- Jun 1, 2005
Bioelectron— Founded
2010s
- Oct 30, 2019
PTC Therapeutics— Acquired By
Drugs by trial phase (2 distinct, 14 trials)
Phase 2 (2 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Ataxia
- Autism Spectrum Disorder
- Autistic Disorder
- Cerebellar Ataxia
- Child Development Disorders, Pervasive
- Deafness
- Disease
- Friedreich Ataxia
- Hearing Loss
- Hearing Loss, Noise-Induced
- Leigh Disease
- Lipid Metabolism, Inborn Errors
- Mitochondrial Diseases
- Motor Neuron Disease
- Muscular Diseases
- Parkinson Disease
- Rett Syndrome
- Sclerosis
- Syndrome
- Tourette Syndrome
Marketed drugs (1)
Recent trials (17)
- NCT02462603Lead sponsorPhase 2Mar 1, 2016
- NCT02462603Study directorPhase 2Mar 1, 2016
- NCT02460679Lead sponsorPhase 2Dec 1, 2015
- NCT02460679Study directorPhase 2Dec 1, 2015
- NCT02300753Lead sponsorN/ANov 21, 2014
- NCT02257983Lead sponsorPhase 2Oct 1, 2014
- NCT02226458Lead sponsorPhase 2Oct 1, 2014
- NCT02104336Study chairPhase 2Aug 1, 2014
- NCT02104336Lead sponsorPhase 2Aug 1, 2014
- NCT02352896Lead sponsorPhase 2Jan 1, 2014
- NCT01962363CollaboratorPhase 2Oct 1, 2013
- NCT01923584CollaboratorPhase 2Sep 1, 2013
- NCT01822249Lead sponsorPhase 2Jan 1, 2013
- NCT01728064Lead sponsorPhase 2Dec 1, 2012
- NCT01719523CollaboratorPhase 1Oct 1, 2012
Details
- Founded
- Mountain View, CA, US Jun 1, 2005
- Last known activity
- Mar 1, 2016
Notes
formerly Edison Pharmaceuticals Inc